Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
TRENDS
Japan’s 1st DPP-4/SGLT-2 Pair to Hit Shelves Shortly, Will Shift to Combo Drugs Gain Ground?
By Reiji Anasako The Japanese diabetes market has seen an increasing number of fixed-dose combination drugs pairing dipeptidyl peptidase-4 (DPP-4) inhibitors with other agents with different mechanisms of action. Following DPP-4 combos with biguanides and thiazolidinediones, Canalia (teneligliptin + canagliflozin)…
To read the full story
TRENDS
- Top 10 PHARMA JAPAN Articles of 2025
December 23, 2025
- Top 10 PHARMA JAPAN Articles of 2024
December 25, 2024
- Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
- Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
- 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…